INTRODUCTION
============

Pleomorphic carcinoma of the lung (PCL) is a rare tumor, which constitutes approximately 0.1-0.4% of all lung cancers, and has a poor clinical outcome ([@B1]-[@B3]). Histologically PCLs exhibit characteristic tumor components, i.e., malignant epithelial and homologous sarcomatoid spindle/giant cells. The recently updated WHO classification defined pleomorphic carcinoma as \"a poorly differentiated non-small cell carcinoma, namely, as a squamous cell carcinoma, adenocarcinoma or large cell carcinoma, containing spindle cells and/or giant cells, or as a carcinoma consisting only of spindle cells and giant cells and added that the pleomorphic component should comprise at least 10% of the neoplasm\" ([@B4]). The co-expression of cytokeratin and vimentin is helpful in the diagnosis of PCL ([@B5]-[@B9]). The immunoreactivity of epithelial and mesenchymal markers in PCL suggests that PCL is a malignant neoplasm of epithelial origin ([@B10]-[@B13]). However, a variety of morphologic features in PCL suggest the possibility that PCL might be a heterogeneous group of tumors rather than an epithelial cell-derived malignant tumor.

CD99 is a transmembrane protein encoded by the *MIC-2* gene and is characteristically expressed in the Ewing family of tumors/PNETs, a group of small cell tumors of childhood and adolescence with a specific *EWS/ETS* gene rearrangement ([@B14]-[@B16]). In addition, its expression also has been reported in lymphoblastic lymphoma/leukemia and some epithelial tumors ([@B17]-[@B19]). Recently CD99 was found to be a critical molecule that contributes to the regulation of apoptosis and the cell cycle in malignant cells ([@B20]). Nevertheless, to the best of our knowledge no study of the expression pattern and biological role of CD99 has been undertaken in PCL. Thus, the aim of this study was to evaluate the expression of CD99/MIC-2 protein in a series of PCLs and to investigate whether this expression is related to morphological differentiation or prognostic implications.

MATERIALS AND METHODS
=====================

Patients and samples
--------------------

Formalin-fixed paraffin-embedded blocks of 21 cases of pleomorphic carcinomas undergoing surgical resection (14 pneumonectomies, 7 lobectomies) between January 1, 1991 and July 30, 2002 were retrieved from the histopathology files at Seoul National University Hospital and at Samsung Medical Center, Seoul, Korea. Each tumor was reevaluated with regard to staging and histologic types of tumor component. Tumor staging was performed using the TNM classification system of the International Union Against Cancer. Follow-up data were obtained from medical records.

Immunohistochemistry
--------------------

Tissue samples were processed using a heat-induced antigen retrieval procedure and immunostained using the conventional streptavidin-ABC technique. Tissues were treated with mouse monoclonal anti-CD99 antibody (clone YG32, DiNonA, Seoul, Korea) at a dilution of 1:250. Other antibodies used were; anti-cytokeratin 7 (clone OV-TL 12/30, Dako, Glostrup, Denmark; dilution 1:100), anti-EMA (clone E29, Dako, Glostrup, Denmark; dilution 1:100), anti-vimentin (clone V9, Dako, Glostrup, Denmark; dilution 1:50) and anti-TTF-1 (clone 8G7G3/1, Dako, Glostrup, Denmark; dilution 1:100). As a negative control, primary antibodies were replaced by irrelevant isotype-matched antibodies. Samples were determined as immunoreactive for CD99 if cell membrane staining or granular intracytoplasmic dotting was observed, for TTF-1 if nuclear staining was present, and for the other if cytoplasmic staining was observed. Tissues were deemed as negative if staining was either completely absent or observed in less than 10% of neoplastic cells.

Statistical analysis
--------------------

Correlations between immunohistochemical profiles and the patients\' clinical and pathological characteristics were analyzed using the chi-square test or Fisher\'s exact test (2-sided) using SPSS version 10.0. *p* values for *p*\<0.05 were taken to be statistically significant.

RESULTS
=======

Clinical findings
-----------------

As summarized in [Table 1](#T1){ref-type="table"}, a total of 21 patients were included in the study. They included 20 men and 1 woman and ranged in age from 50 to 91 yr at the time of surgery (mean age 65 yr). A large number of patients had a tumor onset age of \>60 yr (12 patients, 57.1%). Pathological staging was performed according to the TNM classification of the International Union Against Cancer. Of the 21 patients, 3 patients were at Stage IIA, 9 patients at Stage IIB, 6 patients at Stage IIIA, and 3 patients at Stage IIIB. Follow-up of these patients revealed that 12 patients (57.1%) died of PCL.

Pathologic and immunohistochemical findings
-------------------------------------------

Microscopically, 15 cases contained non-small cell carcinoma combined with sarcomatous components, whereas 6 cases showed only sarcomatous areas without evidence of carcinoma. The carcinomas in these 15 cases were large cell carcinoma in 8 cases, adenocarcinoma in 4, and squamous cell carcinoma in 3. All 21 cases contained spindle cells or giant cells or a mixture of these cell types ([Fig. 1A, B](#F1){ref-type="fig"}).

Of the 21 cases, 7 were composed exclusively of spindle cells that were arranged in long fascicles and resembled either leiomyosarcoma or fibrosarcoma. Eight cases consisted of pleomorphic cells with abundant cytoplasm and multinucleated giant cells. Six cases contained a mixture of spindle cells and giant cells. Of 6 cases with only sarcomatous components, 3 showed pure spindle cell elements, and 3 demonstrated a mixture of two sarcomatous components. Because of the morphologic difference between spindle cells and giant cells in PLC, it was speculated that the expression patterns of various proteins on these cells might differ and be correlated with the clinicopathological characteristics of PCL. Thus, we examined the expression pattern of CD99 on the spindle and giant cells of PLC, respectively.

The immunohistochemistry result of the present study are summarized in [Table 2](#T2){ref-type="table"}. In 15 cases containing carcinomas, all carcinomatous components were immunoreactive for cytokeratin 7, and epithelial membrane antigen (EMA), whereas cytokeratin 20 was not expressed on any carcinomatous or sarcomatous component. The sarcomatous components of all 21 cases were positive for vimentin. Of 13 cases containing spindle cells, CK7 was expressed on spindle cells in 6 cases (43%), TTF-1 in 2 (15%), and CD99 in 11 (85%). Of 14 cases containing giant cells as a sarcomatous component, six cases (57%) were immunoreactive for CK7, 2 (14%) for TTF-1, and 9 (64%) for CD99. TTF-1 was expressed in 5 of 15 cases containing a carcinomatous component, 3 of which were adenocarcinomas and 2 were large cell carcinomas. However, the components of squamous cell carcinoma in three PLCs were negative for TTF-1.

The expression of CD99 in carcinoma was observed in 7 of 15 PCLs. These were as large cell carcinomas in 3 cases, adenocarcinomas in 2, and squamous cell carcinoma in 2 ([Fig. 2A](#F2){ref-type="fig"}). Immnoreactivity for CD99 in sarcomatoid components was intense and diffuse on the cell membrane ([Fig. 2B-D](#F2){ref-type="fig"}). The expression patterns of TTF-1 and CD99 were not statistically related to clinical or pathological parameters, such as histological subtype and staging of PCL.

DISCUSSION
==========

The CD99 protein is ubiquitously expressed in a variety of human normal tissues and malignant cells ([@B21]-[@B24]). In normal tissue CD99 is highly expressed in cortical thymocytes, pancreatic islet cells, granulosa cells of the ovary, Sertoli\'s cells and ependymal cells. It is also expressed on fibroblasts, endothelial cells, smooth muscle cells and respiratory epithelial cells in which the level of expression is relatively low ([@B24], [@B25]). Even though CD99 is known to be a specific marker for Ewing/PNET, it is expressed in a variety of tumors ([@B20]-[@B22], [@B24]-[@B26]). With respect to neoplasms of the lung, CD99 is expressed in 25% of pulmonary neuroendocrine tumors and is preferentially confined to typical carcinoids ([@B19]). It is generally accepted that CD99 is not a specific marker for a particular subset of neoplasms. The present study demonstrates that CD99 expression is not only shown by spindle cells and giant cells in PCL, rather all cases containing a carcinomatous component showed various degrees of CD 99 positivity. In terms of sarcomatous component, the percentage of CD99-positive cells was higher in spindle cells than in giant cells. Our results support the concept that CD99/MIC-2 is not a specific marker for distinguishing a particular subset of human tumors. Moreover, it has been reported that CD99 plays critical role in the invasion, motility, and proliferation of malignant cells ([@B27]-[@B33]). Pelosi et al. reported a statistically significant relationship between the number of CD99 positive cells and the presence of local invasion and/or distant metastasis, and the Ki-67 index in gastrointestinal and pulmonary neuroendocrine tumors ([@B19]). These findings suggest that CD99 may be involved in cell-to-cell adhesion of neuroendocrine tumor cells and in downregulation of their proliferative activity. Thus, to explore the biological implication of CD99 in PCL we analyzed patient clinico-pathologic data. However, CD99 expression in PCL was not found to be correlated with patient prognostic parameters. These findings suggest that the expression of CD99 in PCL does not contribute to the anti-proliferation PCL tumor cells.

Although the histogenesis of PCL has not been clearly explored, several groups have suggested the possibility that PCL is a carcinoma with divergent sarcomatous differentiation, rather than being a collision neoplasm. Recently Rossi et al. studied 58 cases of PCL that showed immunoreactivity for CK7 and TTF-1 in the epithelial and sarcomatous elements ([@B34]). In addition, three groups have demonstrated that the epithelial and sarcomatous components of PCL show the same genetic abnormalities by microdissection analysis ([@B35]-[@B37]). These findings support the concept that the sarcomatous components of PCL might be derived from epithelial components. Like CK7, CD99 was also expressed on spindle and/or giant cells as well as PCL carcinomas in the present study. However, these findings inadequately support the concept that spindle and giant cells are derived from carcinoma because CD99 is more widely expressed on human mesenchymal components and sarcomas than carcinomas. Thus, it is more likely that the expression of CD99 on sarcomatous component of PLC reflects tumor cell mesenchymal differentiation status.

In summary, CD 99 was found to be widely expressed in both sarcomatoid and epithelial components in PCL, like other epithelial markers. Although the biological implications of its expression in PCL remain unclear, the clinicopathological analysis demonstrated no direct correlation between the expressions of CD99 in PCL and the clinical indices of PCL patients.
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![(**A**) Spindle cells of sarmocomatous areas whirled around carcinomatous component (H&E, ×200). (**B**) Giant cells are admixed with spindle cell components (H&E, ×200). (**C**) Spindle cells show immunoreactivity for cytokeratin 7 (×400). (**D**) TTF-1 nuclear stainings are detected in spindle cells in sarcomatous area (×400).](jkms-20-50-g001){#F1}

![(**A**) Carcinoma component of PCL showing CD99 surface expression on tumor cells (×200). (**B**, **C**) CD99 immunoreacitivity was detected on spindle cells (**B**: ×200, **C**: ×400). (**D**) CD99 is observed on giant cells (×400).](jkms-20-50-g002){#F2}
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Immunohistochemistry results
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P, positive; -, absence of these component; N, negative; S, spindle cell component; G, giant cell component; EP, epithelial cell component.
